223 related articles for article (PubMed ID: 30913525)
1. Synthesis and anti-cancer evaluation of folic acid-peptide- paclitaxel conjugates for addressing drug resistance.
Dai Y; Cai X; Bi X; Liu C; Yue N; Zhu Y; Zhou J; Fu M; Huang W; Qian H
Eur J Med Chem; 2019 Jun; 171():104-115. PubMed ID: 30913525
[TBL] [Abstract][Full Text] [Related]
2. Systematic evaluation of multifunctional paclitaxel-loaded polymeric mixed micelles as a potential anticancer remedy to overcome multidrug resistance.
Zhang J; Zhao X; Chen Q; Yin X; Xin X; Li K; Qiao M; Hu H; Chen D; Zhao X
Acta Biomater; 2017 Mar; 50():381-395. PubMed ID: 27956367
[TBL] [Abstract][Full Text] [Related]
3. Trimethyl chitosan based conjugates for oral and intravenous delivery of paclitaxel.
He R; Yin C
Acta Biomater; 2017 Apr; 53():355-366. PubMed ID: 28189812
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of folate targeted biodegradable polymer-paclitaxel conjugate micelles on EMT-6 breast cancer model.
Wu D; Zheng Y; Hu X; Fan Z; Jing X
Mater Sci Eng C Mater Biol Appl; 2015 Aug; 53():68-75. PubMed ID: 26042692
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy.
Li B; Tan T; Chu W; Zhang Y; Ye Y; Wang S; Qin Y; Tang J; Cao X
Drug Deliv; 2022 Dec; 29(1):75-88. PubMed ID: 34964421
[TBL] [Abstract][Full Text] [Related]
6. Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity.
Rezazadeh M; Emami J; Hassanzadeh F; Sadeghi H; Rostami M; Mohammadkhani H
Curr Drug Deliv; 2017; 14(8):1189-1200. PubMed ID: 28472908
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro.
Liu S; Zhang K; Zhu Q; Shen Q; Zhang Q; Yu J; Chen Y; Lu W
Bioorg Med Chem; 2019 Apr; 27(7):1405-1413. PubMed ID: 30819618
[TBL] [Abstract][Full Text] [Related]
9. Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers.
Chen FQ; Zhang JM; Fang XF; Yu H; Liu YL; Li H; Wang YT; Chen MW
Acta Pharmacol Sin; 2017 Jun; 38(6):859-873. PubMed ID: 28260803
[TBL] [Abstract][Full Text] [Related]
10. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines.
Wang Y; Yu L; Han L; Sha X; Fang X
Int J Pharm; 2007 Jun; 337(1-2):63-73. PubMed ID: 17289311
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of redox-sensitive gonadotropin-releasing hormone receptor-targeting peptide conjugates.
Dai Y; Yue N; Liu C; Cai X; Su X; Bi X; Li Q; Li C; Huang W; Qian H
Bioorg Chem; 2019 Jul; 88():102945. PubMed ID: 31054430
[TBL] [Abstract][Full Text] [Related]
13. Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles.
Wang J
Drug Des Devel Ther; 2020; 14():823-832. PubMed ID: 32161442
[TBL] [Abstract][Full Text] [Related]
14. Tumor-targeting micelles based on folic acid and α-tocopherol succinate conjugated hyaluronic acid for paclitaxel delivery.
Zhang X; Liang N; Gong X; Kawashima Y; Cui F; Sun S
Colloids Surf B Biointerfaces; 2019 May; 177():11-18. PubMed ID: 30690425
[TBL] [Abstract][Full Text] [Related]
15. Pro-apoptotic cationic host defense peptides rich in lysine or arginine to reverse drug resistance by disrupting tumor cell membrane.
Dai Y; Cai X; Shi W; Bi X; Su X; Pan M; Li H; Lin H; Huang W; Qian H
Amino Acids; 2017 Sep; 49(9):1601-1610. PubMed ID: 28664269
[TBL] [Abstract][Full Text] [Related]
16. Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy.
Shan L; Liu M; Wu C; Zhao L; Li S; Xu L; Cao W; Gao G; Gu Y
Int J Nanomedicine; 2015; 10():5571-91. PubMed ID: 26366078
[TBL] [Abstract][Full Text] [Related]
17. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.
Shan L; Zhuo X; Zhang F; Dai Y; Zhu G; Yung BC; Fan W; Zhai K; Jacobson O; Kiesewetter DO; Ma Y; Gao G; Chen X
Theranostics; 2018; 8(7):2018-2030. PubMed ID: 29556370
[TBL] [Abstract][Full Text] [Related]
18. Co-Delivery of Paclitaxel and shMCL-1 by Folic Acid-Modified Nonviral Vector to Overcome Cancer Chemotherapy Resistance.
Nie W; Wang B; Mi X; Chen J; Yu T; Miao J; Lin Y; Yang T; Ran M; Hong Z; Liu X; Liang X; Qian Z; Gao X
Small Methods; 2021 May; 5(5):e2001132. PubMed ID: 34928100
[TBL] [Abstract][Full Text] [Related]
19. Nanoprodrug of retinoic acid-modified paclitaxel.
Zhou Z; Yan J; Sun T; Wang X; Xie Z
Org Biomol Chem; 2017 Nov; 15(45):9611-9615. PubMed ID: 29106434
[TBL] [Abstract][Full Text] [Related]
20. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
